Is adjuvant chemotherapy necessary for 2014 FIGO stage IC adult granulosa cell tumor?: Multicentric Turkish study.

Autor: Erdogan O; Department of Gynecologic Oncology, Tepecik Training and Research Hospital, Izmir, Turkey., Kilic C; Department of Gynecologic Oncology, Hitit University, Corum, Turkey., Cakir C; Department of Gynecologic Oncology, Etlik Zubeyde Hanim Women's Health Training and Research Hospital, Faculty of Medicine, University of Health Sciences, Ankara, Turkey., Kilic F; Department of Gynecologic Oncology, Ankara City Hospital, Ankara, Turkey., Oktar O; Department of Gynecologic Oncology, Etlik Zubeyde Hanim Women's Health Training and Research Hospital, Faculty of Medicine, University of Health Sciences, Ankara, Turkey., Ersak B; Department of Gynecologic Oncology, Ankara City Hospital, Ankara, Turkey., Sahin M; Department of Gynecologic Oncology, Ankara City Hospital, Ankara, Turkey., Tokalioglu A; Department of Gynecologic Oncology, Ankara City Hospital, Ankara, Turkey., Kocak O; Department of Gynecologic Oncology, Hitit University, Corum, Turkey., Ozturk C; Ankara University, Faculty of Medicine, Ankara, Turkey., Gorgulu G; Department of Gynecologic Oncology, Tepecik Training and Research Hospital, Izmir, Turkey., Gokkaya M; Department of Gynecologic Oncology, Antalya Training and Research Hospital, Antalya, Turkey., Selcuk I; Department of Gynecologic Oncology, Zekai Tahir Burak Training and Research Hospital, Ankara, Turkey., Korkmaz V; Department of Gynecologic Oncology, Etlik Zubeyde Hanim Women's Health Training and Research Hospital, Faculty of Medicine, University of Health Sciences, Ankara, Turkey., Comert GK; Department of Gynecologic Oncology, Ankara City Hospital, Ankara, Turkey., Toptas T; Department of Gynecologic Oncology, Antalya Training and Research Hospital, Antalya, Turkey., Ureyen I; Department of Gynecologic Oncology, Antalya Training and Research Hospital, Antalya, Turkey., Ucar G; Department of Medical Oncology, Ankara City Hospital, Ankara, Turkey., Taskin S; Ankara University, Faculty of Medicine, Ankara, Turkey., Tasci T; Department of Gynecologic Oncology, Bahcesehir University, Istanbul, Turkey., Uncu D; Department of Medical Oncology, Ankara City Hospital, Ankara, Turkey., Narin MA; Department of Gynecologic Oncology, Adana City Hospital, Adana, Turkey., Boran N; Department of Gynecologic Oncology, Etlik Zubeyde Hanim Women's Health Training and Research Hospital, Faculty of Medicine, University of Health Sciences, Ankara, Turkey., Ozdal B; Department of Gynecologic Oncology, Zekai Tahir Burak Training and Research Hospital, Ankara, Turkey., Tekin OM; Department of Gynecologic Oncology, Ankara City Hospital, Ankara, Turkey., Ustun Y; Department of Gynecologic Oncology, Etlik Zubeyde Hanim Women's Health Training and Research Hospital, Faculty of Medicine, University of Health Sciences, Ankara, Turkey., Sancı M; Department of Gynecologic Oncology, Tepecik Training and Research Hospital, Izmir, Turkey., Ortac F; Ankara University, Faculty of Medicine, Ankara, Turkey., Turan T; Department of Gynecologic Oncology, Ankara City Hospital, Ankara, Turkey.
Jazyk: angličtina
Zdroj: Asia-Pacific journal of clinical oncology [Asia Pac J Clin Oncol] 2024 Feb; Vol. 20 (1), pp. 46-54. Date of Electronic Publication: 2023 Apr 24.
DOI: 10.1111/ajco.13942
Abstrakt: Aim: The aim of our study is to examine the clinical, surgical, and pathological factors of stage 1C adult granulosa cell tumor (AGCT) patients and to investigate the effects of adjuvant therapy on recurrence and survival rates in this patient group.
Methods: Out of a total of 415 AGCT patients treated by 10 tertiary oncology centers participating in the study, 63 (15.2%) patients with 2014 FIGO stage IC constituted the study group. The FIGO 2014 system was used for staging. Patient group who received adjuvant chemotherapy was compared with patient group who did not receive adjuvant chemotherapy in terms of disease-free survival (DFS), and disease-specific survival.
Results: The 5-year DFS of the study cohort was 89%, and the 10-year DFS was 85%. Those who received adjuvant chemotherapy and those who did not were similar in terms of clinical, surgical and pathological factors, except for peritoneal cytology. In the univariate analysis, none of the clinical, surgical or pathological factors were significant for DFS. Adjuvant chemotherapy and type of treatment protocol had no impact on DFS.
Conclusion: Adjuvant chemotherapy was not associated with improved DFS and overall survival in stage IC AGCT. Multicentric and randomized controlled studies are needed for early stage AGCT in order to confirm these results and reach accurate conclusions.
(© 2023 John Wiley & Sons Australia, Ltd.)
Databáze: MEDLINE
Externí odkaz: